CTLA4 and melanoma: Anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) was approved in 2011 for the treatment of advanced melanoma, and other immune checkpoint inhibitors (ICIs) were quickly approved by the Food and Drug Administration (24).